124 related articles for article (PubMed ID: 35776191)
41. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
42. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
43. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.
Kumar A; Pathak P; Purkait S; Faruq M; Jha P; Mallick S; Suri V; Sharma MC; Suri A; Sarkar C
Cancer Genet; 2015 Mar; 208(3):91-5. PubMed ID: 25794445
[TBL] [Abstract][Full Text] [Related]
44. Vestigial-Like 3 Plays an Important Role in Osteoblast Differentiation by Regulating the Expression of Osteogenic Transcription Factors and BMP Signaling.
Yuan H; Ikegame M; Fukuhara Y; Takemoto F; Yu Y; Teramachi J; Weng Y; Guo J; Yamada D; Takarada T; Li Y; Okamura H; Zhang B
Calcif Tissue Int; 2022 Sep; 111(3):331-344. PubMed ID: 35750933
[TBL] [Abstract][Full Text] [Related]
45. Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma.
Hofvander J; Tayebwa J; Nilsson J; Magnusson L; Brosjö O; Larsson O; Vult von Steyern F; Mandahl N; Fletcher CD; Mertens F
Clin Cancer Res; 2015 Feb; 21(4):864-9. PubMed ID: 25516889
[TBL] [Abstract][Full Text] [Related]
46. Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma.
Antonescu CR; Sung YS; Chen CL; Zhang L; Chen HW; Singer S; Agaram NP; Sboner A; Fletcher CD
Genes Chromosomes Cancer; 2014 Feb; 53(2):183-93. PubMed ID: 24285434
[TBL] [Abstract][Full Text] [Related]
47. Diverse
Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional and posttranscriptional regulation of the SMC-selective blood pressure-associated gene, ARHGAP42.
Mangum KD; Freeman EJ; Magin JC; Taylor JM; Mack CP
Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H413-H424. PubMed ID: 31886719
[TBL] [Abstract][Full Text] [Related]
49. TEAD1 inhibits prolactin gene expression in cultured human uterine decidual cells.
Kessler CA; Bachurski CJ; Schroeder J; Stanek J; Handwerger S
Mol Cell Endocrinol; 2008 Nov; 295(1-2):32-8. PubMed ID: 18775765
[TBL] [Abstract][Full Text] [Related]
50. The transcription factor TEAD1 represses smooth muscle-specific gene expression by abolishing myocardin function.
Liu F; Wang X; Hu G; Wang Y; Zhou J
J Biol Chem; 2014 Feb; 289(6):3308-16. PubMed ID: 24344135
[TBL] [Abstract][Full Text] [Related]
51. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
52. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
53. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
Knezevich SR; McFadden DE; Tao W; Lim JF; Sorensen PH
Nat Genet; 1998 Feb; 18(2):184-7. PubMed ID: 9462753
[TBL] [Abstract][Full Text] [Related]
54. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas.
Hélias-Rodzewicz Z; Pérot G; Chibon F; Ferreira C; Lagarde P; Terrier P; Coindre JM; Aurias A
Genes Chromosomes Cancer; 2010 Dec; 49(12):1161-71. PubMed ID: 20842732
[TBL] [Abstract][Full Text] [Related]
55. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
[TBL] [Abstract][Full Text] [Related]
56. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.
Botton T; Talevich E; Mishra VK; Zhang T; Shain AH; Berquet C; Gagnon A; Judson RL; Ballotti R; Ribas A; Herlyn M; Rocchi S; Brown KM; Hayward NK; Yeh I; Bastian BC
Cell Rep; 2019 Oct; 29(3):573-588.e7. PubMed ID: 31618628
[TBL] [Abstract][Full Text] [Related]
57. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
[TBL] [Abstract][Full Text] [Related]
58. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
Corcoran RB; Dias-Santagata D; Bergethon K; Iafrate AJ; Settleman J; Engelman JA
Sci Signal; 2010 Nov; 3(149):ra84. PubMed ID: 21098728
[TBL] [Abstract][Full Text] [Related]
59. VGLL3 activates inflammatory responses by inducing interleukin-1α secretion.
Takakura Y; Hori N; Terada N; Machida M; Yamaguchi N; Takano H; Yamaguchi N
FASEB J; 2021 Nov; 35(11):e21996. PubMed ID: 34679187
[TBL] [Abstract][Full Text] [Related]
60. Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Puls F; Agaimy A; Flucke U; Mentzel T; Sumathi VP; Ploegmakers M; Stoehr R; Kindblom LG; Hansson M; Sydow S; Arbajian E; Mertens F
Am J Surg Pathol; 2020 May; 44(5):594-606. PubMed ID: 31913156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
